Metabolic effects of vanadyl sulfate in humans with non-insulin- dependent diabetes mellitus: In vivo and in vitro studies

Metabolism: Clinical and Experimental

Volumn 49, Issue 3, 2000, Pages 400-410

  Goldfine, Allison B ^a,b,c   Patti, Mary Elizabeth ^a,b,c   Zuberi, Lubna ^a,b,c   Goldstein, Barry J ^a,b,c   LeBlanc, Raeann ^a,b,c   Landaker, Edwin J ^a,b,c   Jiang, Zhen Y ^a,b,c   Willsky, Gail R ^a,b,c   Kahn, C Ronald ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; GLYCOGEN SYNTHASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VANADYL SULFATE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 0034117351     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(00)90418-9     Document Type: Article

References (84)

1. Tamura S, Brown TA, Whipple JH, et al: A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes. J Biol Chem 259:6650-6658, 1984
2. Meyerovitch J, Backer JM, Kahn CR: Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats. J Clin Invest 84:976-983, 1989
3. Strout HV, Vicario PP, Saperstein R, et al: The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity nor phosphorylation in mouse diaphragm in vivo. Endocrinology 124:1918-1924, 1989
4. Nechay BR, Nanninga LB, Nechay PSE, et al: Role of vanadium in biology. Fed Proc 45:123-132, 1986
5. Waters MD: Toxicology of vanadium, in Goyer RA, Mehlman MA (eds): Advances in Modem Toxicology, vol 2. Toxicology of Trace Elements. Washington, DC, Hemisphere, 1977, p 147
6. Nadel JA: Editorial: Genetics importance of platelet activating factor in asthma and possibly other inflammatory states. J Clin Invest 97:2689-2690, 1996
7. Shechter Y, Karlish SJD: Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature 284:556-558, 1980
8. + concentration and electrophysiological characteristics of mouse skeletal muscle fiber. Physiol Bohemoslov 30:1-10, 1981
9. Shechter Y, Ron A: Effect of depletion of bicarbonate or phosphate ions on insulin action in rat adipocytes. Further characterization of the receptor-effector system. J Biol Chem 261:14951-14954, 1986
10. Degani H, Gochin M, Karlish SJD, et al: Electron paramagnetic studies and insulin-like effects of vanadium in rat adipocytes. Biochemistry 20:5795-5799, 1981
11. Tamura S, Brown TA, Dubler RE, et al: Insulin-like effect of vanadate on adipocyte glycogen synthase and on phosphorylation of 95,000 dalton subunit of insulin receptor. Biochem Biophys Res Commun 113:80-86, 1983
12. Werdan K, Bauriedel G, Fisher B, et al: Stimulatory and inhibitory action of vanadate on potassium uptake and cellular sodium and potassium in heart cells in culture. Biochim Biophys Acta 23:79-83, 1982
13. Rodan GA, Fleisch HA: Bisphosphonates: Mechanisms of action. J Clin Invest 97:2692-2696, 1996
14. Smith JB: Vanadium ions stimulate DNA synthesis in Swiss mouse 3T3 and 3T6 cells. Proc Natl Acad Sci USA 80:6162-6166, 1983
15. Canalis E: Effect of sodium vanadate on deoxyribonucleic acid and protein synthesis in cultured rat clavaria. Endocrinology 116:855-862, 1985
16. Meyerovitch J, Farfel Z, Sack J, et al: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. J Biol Chem 262:6658-6662, 1987
17. Blondel O, Bailte D, Portha B: In vivo insulin resistance in streptozotocin-diabetic rats - Evidence for reversal following oral vanadate treatment. Diabetologia 32:185-190, 1989
18. Meyerovitch J, Rothenberg PL, Shechter Y, et al: Vanadate normalizes hyperglycemia in two mouse models of non-insulin dependent diabetes mellitus. J Clin Invest 87:1286-1294, 1991
19. Brichard SM, Bailey CJ, Henquin JC: Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes 39:1326-1332, 1990
20. Brichard SM, Omgemba LN, Henquin JC: Oral vanadate decreases muscle insulin resistance in obese fa/fa rats. Diabetologia 35:522-527, 1990
21. Brichard SM, Bailey CJ, Henquin JC: Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology 125:2510-2516, 1989
22. Lyonnet S, Martz A: L'emploithérapeutique de derivés du vanadium. Presse Med 1:191-192, 1899
23. Cohen N, Halberstam M, Shlimovich P, et al: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 95:2501-2509, 1995
24. Boden G, Chen Z, Ruiz J, et al: Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 45:1130-1135, 1996
25. Cusi K, Cukeir S, DeFronzo RA, et al: Metabolic effects of treatment with vanadyl sulfate in NIDDM. Diabetes 46:34A, 1997 (abstr)
26. Goldfine AB, Simonson DC, Folli F, et al: Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus: In vivo and in vitro studies. J Clin Endocrinol Metab 80:3311-3320, 1995
27. Halberstam M, Cohen A, Shlimovich P, et al: Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 45:659-666, 1996
28. DeFronzo RA, Tobin JD. Andres R: Glucose clamp techniques: A method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
29. McGuire EA, Helderman JH, Tobin JD, et al: Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol 41:565-573, 1976
30. Ferrannini E, DelPrato S, DeFronzo RA: Glucose kinetics and tracer methods, in Clarke WL, Larner J, Pohl SL (eds): Methods in Diabetics Research, vol 2. Clinical Methods. New York, NY, Wiley Interscience, 1986
31. DeFronzo RA, Ferrannini E, Simonson DC: Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387-395, 1989
32. Bergman RN, Finegold DT, Ader M: Assessment of insulin sensitivity in vivo. Endocr Rev 6:45-86, 1985
33. Cowan JS, Hetenyi G Jr: Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method. Metabolism 20:360-372, 1971
34. Ferrannini E: The theoretical basis of indirect calorimetry: A review. Metabolism 37:287-301, 1988
35. Chu Y, Solski PA, Khosravi-Far R, et al: The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 271:6497-6501, 1996
36. Lusk G: Animal calorimetry: Analysis of the oxidation of mixtures of carbohydrate and fat. J Biol Chem 59:41-42, 1924
37. Folli F, Saad MJA, Backer JM, et al: Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. J Clin Invest 92:1787-1794, 1993
38. Mandarino LJ, Wright KS, Verity LS, et al: Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative and nonoxidative glucose metabolism. J Clin Invest 80:655-663, 1987
39. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72:248-254, 1976
40. Tonks NK, Diltz CD, Fischer EH: Purification and assay of cd-45: An integral membrane protein-tyrosine phosphatase. Methods Enzymol 201:442-451, 1991
41. Slater TF, Sawyer BC: The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. Biochem J 123:805-814, 1971
42. Gennaro WD, Van Norman JD: Quantitation of free, total and antibody-bound insulin in insulin treated diabetes. Clin Chem 21:873-879, 1975
43. Szafranek J, Pfaffenberger CD, Horning EC: The mass spectra of some per-O-acetylaldononitriles. Carbohydr Res 38:97-105, 1974
44. Seiler HG: Analytical procedures for the determination of vanadium in biological materials. Met Ions Biol Syst 31:671-688, 1995
45. Bhanot S, McNeill JH: Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension 24:625-632, 1994
46. Bhanot S, McNeill JH, Bryer-Ash M: Vanadyl sulfate prevents fructose-induced hyperinsulinemia and hypertension in rats. Hypertension 23:308-312, 1994
47. Elmendorf JS, Damrau-Abney A, Smith TR, et al: Insulin-stimulated phosphatidylinositol 3-kinase activity and 2-deoxy-D-glucose uptake in rat skeletal muscle. Biochem Biophys Res Commun 208:1147-1153, 1995
48. Okada T, Kawano Y, Sakakibara T, et al: Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes: Studies with a selective inhibitor wortmannin. J Biol Chem 269:3568-3573, 1994
49. Clarke JF, Young PW, Yonezawa K, et al: Inhibition of the translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin. Biochem J 300:631-635, 1994
50. Hara K, Yonezawa K, Sakaue H, et al: Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for ras activation in CHO cells. Proc Natl Acad Sci USA 91:7415-7419, 1994
51. Berger J, Hayes N, Szalkowski DM, et al: PI 3-kinase activation is required for insulin stimulation of glucose transport into L6 myotubes. Biochem Biophys Res Commun 205:570-576, 1994
52. Ramanadham S, Mongold JJ, Brownsey RW, et al: Oral vanadyl sulfate in treatment of diabetes mellitus in rats. Am J Physiol 257:H904-H911, 1989
53. Heyliger CE, Tahiliani AG, McNeill JH: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227:1474-1477, 1985
54. Shechter Y: Insulin mimetic effects of vanadate: Possible implications for future treatment of diabetes. Diabetes 39:1-5, 1990
55. Aharon Y, Mevorach M, Shamoon H: Vanadyl sulfate does not enhance insulin action in patients with IDDM. Diabetes 46:95A, 1997 (abstr)
56. Cam MC, Faun J, McNeill JH: Concentration-dependent glucose-lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin-diabetic rats. Metabolism 44:332-339, 1995
57. Boden G, Chen Z, Ruiz J, et al: Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 45:1130-1135, 1996
58. Curran GL, Azarnoff DL, Bolinger RE: Effect of cholesterol synthesis inhibition in normocholesteremic young men. J Clin Invest 38:1251-1261, 1959
59. Azamoff DL: Site of vanadium inhibition of cholesterol biosynthesis. J Am Chem Soc 79:2968-2969, 1957
60. Hudson TGF: The effects of vanadium on metabolism (continued), in Anonymous (ed): Vanadium: Toxicology and Biological Significance. New York, NY, Elsevier, 1964, p 30
61. Werden K, Bauriedel G, Fisher B, et al: Stimulatory (insulin-mimetic) and inhibitory (ouabain-like) action of vanadate on potassium uptake and cellular sodium and potassium in heart cells in culture. Biochim Biophys Acta 23:79-93, 1982
62. Curran GL, Costello RL: Reduction of excess cholesterol in the rabbit aorta by inhibition of endogenous cholesterol synthesis. J Exp Med 103:49-56, 1956
63. Ferrannini E, Natali A: Essential hypertension, metabolic disorders and insulin resistance. Am Heart J 121:1274-1282, 1991
64. Shen DC, Shieh SM, Fuh MMT, et al: Resistance to insulin stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 66:580-583, 1988
65. Modon CE, Reaven GM: Evidence of abnormalities of insulin metabolism in rats with spontaneous hypertension. Metabolism 37:303-305, 1988
66. Hwang IS, Ho H, Hoffman BB, et al: Fructose induced insulin resistance and hypertension in rats. Hypertension 12:129-132, 1988
67. McNeill JH, Yuen VG, Hoveyda HR, et al: Bis(maltoloto)oxovanadium (IV) is a potent insulin mimic. J Med Chem 35:1489-1491, 1992
68. Bhanot S, Bryer-Ash M, Cheung A, et al: Bis(maltoloto)oxovanadium (IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats. Diabetes 43:857-861, 1994
69. Oster MH, Llobet JM, Domingo JL, et al: Vanadium treatment of diabetic Sprague-Dawley rats results in tissue vanadium accumulation and pro-oxidant effects. Toxicology 83:115-130, 1993
70. Thompson KH, McNeill JH: Effect of vanadyl sulfate feeding on susceptibility to peroxidative change in diabetic rats. Res Commun Chem Pathol Pharmacol 80:187-200, 1993
71. White MF, Kahn CR: The insulin signaling system. J Biol Chem 269:1-4, 1994
72. Olefsky JM: The insulin receptor: A multifunctional protein. Diabetes 39:1008-1016, 1990
73. Nagase I, Yoshida T, Kumamoto K, et al: Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic β3-adrenergic agonist. J Clin Invest 97:2898-2904, 1996
74. Shisheva A, Shechter Y: Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. Biochemistry 31:8059-8063, 1992
75. Shechter Y, Shisheva A, Lazar R, et al: Hydrophobic carriers of vanadyl ions augment the insulinomimetic actions of vanadyl ions in rat adipocytes. Biochem J 31:8059-8063, 1992
76. Posner BI, Faure R, Burgess JW, et al: Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 269:4596-4604, 1994
77. Kadota S, Fantus GI, Deragon F, et al: Stimulation of insulin-like growth factor II receptor binding and insulin receptor kinase activity in rat adipocytes. J Biol Chem 262:8252-8256, 1987
78. Tobe K, Kadowaki T, Hara K, et al: Sequential activation of MAP kinase activator, MAP kinases, and S6 peptide kinase in intact rat liver following insulin injection. J Biol Chem 267:21089-21097, 1992
79. Kozma SC, Lane HA, Ferrari S, et al: A stimulated S6 kinase from rat liver; identity with the mitogen activated S6 kinase of 3T3 cells. EMBO J 8:4125-4132, 1989
80. Hei Y, Chen X, Pelech S, et al: Skeletal muscle mitogenactivated protein kinases and ribosomal S6 kinases. Suppression in chronic diabetic rats and reversal by vanadium. Diabetes 44:1147-1155, 1995
81. D'Onofrio F, Le MQU, Chiasson JL, et al: Activation of mitogen activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation. Growth Regul 340:269-275, 1994
82. Goldstein BJ: Protein-tyrosine phosphatase and the regulation of insulin action. J Cell Biochem 48:33-42, 1992
83. Swarup G, Cohen S, Garbers DL: Inhibition of membrane phosphotyrosyl protein phosphatase activity by vanadate. Biochem Biophys Res Commun 107:1104-1109, 1982
84. Meyerovitch J, Backer JM, Csermely P, et al: Insulin differentially regulates protein phosphotyrosine phosphatase activity in rat hepatoma cells. Biochemistry 31:10338-10344, 1992